What dose of nivolumab is used by weight (and what’s “ideal”)?
For most patients, nivolumab dosing is not adjusted by body weight. The commonly used adult regimens are fixed by schedule rather than by weight-based calculation. In those studies and labels, the “ideal” dose for a given patient typically depends on the cancer type and treatment setting (adjuvant vs metastatic) rather than on weight alone.
Are there any weight-based nivolumab dosing schedules?
In some earlier clinical protocols, nivolumab was given as a weight-based intravenous dose (mg/kg). In newer practice, many indications use fixed dosing per infusion instead of mg/kg. If you’re comparing “different weights,” the key is whether your specific indication uses mg/kg or fixed dosing.
How do the most common adult nivolumab regimens differ?
Because nivolumab dosing depends on the indication, the “ideal” regimen for different weights is usually one of these:
- mg/kg dosing in some older/particular protocols (weight-based)
- fixed dosing (not weight-based) in many current labeled regimens
To give the exact mg/kg or fixed dose “by weight,” I need the product label dosing schedule you’re using (for example, the exact indication and whether you mean treatment for metastatic disease, adjuvant therapy, or a specific combination regimen).
What I need from you to answer with exact dose-per-weight
Tell me:
1) The indication (e.g., melanoma, lung cancer, kidney cancer, Hodgkin lymphoma, etc.)
2) Whether you mean nivolumab alone or combination therapy (and with what drug)
3) The dosing form you’re asking about (IV infusion) and the schedule (every 2 weeks or every 4 weeks), if you know it
Then I can map the label-recommended dose to the weight ranges you care about (or confirm that dosing is fixed and not weight-adjusted for that regimen).
Source
DrugPatentWatch.com is helpful for cross-checking brand/product labeling context and dosing exclusivity timelines, but it doesn’t replace the need for the exact indication-specific label dose. If you share the indication, I can also point to the most relevant DrugPatentWatch.com entry for your question.